The clinical course of non-muscle invasive bladder cancer after transurethral resection of the tumor with or without subsequent intravesical application of bacillus Calmette-Guerin: The influence of patients gender and age

被引:1
作者
Milosevic, Radovan [1 ,3 ]
Milovic, Novak [1 ,3 ]
Aleksic, Predrag [1 ,3 ]
Lazic, Miodrag [4 ]
Cerovic, Snezana [2 ,3 ]
Prelevic, Rade [1 ]
Spasic, Aleksandar [1 ]
Simic, Dejan [1 ]
Kovacevic, Bozidar [2 ]
机构
[1] Mil Med Acad, Urol Clin, Belgrade 11000, Serbia
[2] Mil Med Acad, Inst Pathol, Belgrade 11000, Serbia
[3] Univ Def, Mil Med Acad, Fac Med, Belgrade, Serbia
[4] Univ Belgrade, Fac Med, Dept Urol, Clin Hosp Ctr Dr Dragisa Misovic, Belgrade, Serbia
关键词
urinary bladder neoplasms; recurrence; sex; age factors; risk factors; immunotherapy; urological surgical procedures; RANDOMIZED-TRIALS; URINARY-BLADDER; SUCCESS STORY; MITOMYCIN-C; THERAPY; RECURRENCE; CARCINOMA; RISK; IMMUNOTHERAPY; METAANALYSIS;
D O I
10.2298/VSP140616003M
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Bacground/Aim. The therapy with intravesical instillation of bacillus Calmette-Guerin (BCG) after transurethral resection (TUR) of tumor is the gold standard of treatment of non-muscle invasive bladder cancer (NMIBC). The role and importance of BCG intravesical therapy in various shape of tumors, were confirmed by our previous investigation. The aim of this study was to examine whether incidence of recurrence and tumor regression differs depending on sex and age of patients. Methods. This study included a total of 899 patients suffering from NIMBC, treated at our institution from January 1, 2007 to March 1, 2013. Two groups of patients were formed: patients underwent TUR + EGG therapy (the group I) and the group II with patients in whom TUR was performed as only therapy. These two groups of patients were divided into subgroups of respondents male and female, age 60 years or younger and older than 60 years. Statistical analysis was performed using chi 2 test and the Kolmogorov-Smirnov test Results. This research suggests that if the frequency of recurrence is seen as the only parameter, considering all the subjects, the lowest recurrence rate was determined in the male subjects, aged 60 years and younger who had received BCG after TUR. A high statistical significance was found in the incidence of recurrence in patients younger than 60 years, depending on the response to the therapy, while in those older than 60 years, the difference was at the level of statistical significance. This can be attributed to a certain degree of infravesical obstruction in older men. Conclusions. Sex and age of patients may have a significant influence on the course and outcome of NMIBC. The disease has the most malignant and most aggressive behavior when present in males older than 60 years.
引用
收藏
页码:596 / 601
页数:6
相关论文
共 21 条
  • [1] EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder
    Babjuk, Marko
    Oosterlinck, Willem
    Sylvester, Richard
    Kaasinen, Eero
    Boehle, Andreas
    Palou-Redorta, Juan
    [J]. EUROPEAN UROLOGY, 2008, 54 (02) : 303 - 314
  • [2] Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer:: A formal meta-analysis of comparative studies on recurrence and toxicity
    Böhle, A
    Jocham, D
    Bock, PR
    [J]. JOURNAL OF UROLOGY, 2003, 169 (01) : 90 - 95
  • [3] Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: A success story with room for improvement
    Brandau, Sven
    Suttmann, Henrik
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2007, 61 (06) : 299 - 305
  • [4] Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines
    Chen, FH
    Langenstroer, P
    Zhang, GJ
    Iwamoto, Y
    See, WA
    [J]. JOURNAL OF UROLOGY, 2003, 170 (05) : 2009 - 2013
  • [5] Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin:: Multivariate analysis of data from four randomized CUETO trials
    Fernandez-Gomez, Jesus
    Solsona, Eduardo
    Unda, Miguel
    Martinez-Pineiro, Luis
    Gonzalez, Marcelino
    Hernandez, Rafael
    Madero, Rosario
    Ojea, Antonio
    Pertusa, Carlos
    Rodriguez-Molina, Jesus
    Emilio Camacho, Jose
    Isorna, Santiago
    Rabadan, Mariano
    Astobieta, Ander
    Montesinos, Manuel
    Muntanola, Pedro
    Gimeno, Anabel
    Blas, Miguel
    Antonio Martinez-Pineiro, Jose
    [J]. EUROPEAN UROLOGY, 2008, 53 (05) : 992 - 1002
  • [6] The Role of Bacillus Calmette-Guerin in the Treatment of Non-Muscle-Invasive Bladder Cancer
    Gontero, Paolo
    Bohle, Andreas
    Malmstrom, Per-Uno
    O'Donnell, Michael A.
    Oderda, Marco
    Sylvester, Richard
    Witjes, Fred
    [J]. EUROPEAN UROLOGY, 2010, 57 (03) : 410 - 429
  • [7] Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials
    Han, Rui Fa
    Pan, Jian Gang
    [J]. UROLOGY, 2006, 67 (06) : 1216 - 1223
  • [8] History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story
    Herr, Harry W.
    Moralest, Alvaro
    [J]. JOURNAL OF UROLOGY, 2008, 179 (01) : 53 - 56
  • [9] Bladder Cancer in 2010 How Far Have We Come?
    Jacobs, Bruce L.
    Lee, Cheryl T.
    Montie, James E.
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2010, 60 (04) : 244 - 272
  • [10] INCIDENCE AND TREATMENT OF COMPLICATIONS OF BACILLUS-CALMETTE-GUERIN INTRAVESICAL THERAPY IN SUPERFICIAL BLADDER-CANCER
    LAMM, DL
    VANDERMEIJDEN, APM
    MORALES, A
    BROSMAN, SA
    CATALONA, WJ
    HERR, HW
    SOLOWAY, MS
    STEG, A
    DEBRUYNE, FMJ
    [J]. JOURNAL OF UROLOGY, 1992, 147 (03) : 596 - 600